Needham Initiates Coverage On Pulse Biosciences with Buy Rating, Announces Price Target of $58

Benzinga Newsdesk www.benzinga.com Neutral 70.7%

Neg 0% Neu 70.7% Pos 0%

Needham analyst Mike Matson initiates coverage on Pulse Biosciences (NASDAQ:PLSE) with a Buy rating and announces Price Target of $58.